KalVista Pharmaceuticals, Inc.
NASDAQ:KALVBiotechnology
+$0.00 today
- Market cap
- $1.44B
- Beta
- -0.11
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$2.74
Volume 4.26M
Average 3.47M
KALV Purchases of Investments
Cash used to buy marketable securities and other investments.
KalVista Pharmaceuticals, Inc.NASDAQ: KALV
Purchases of Investments · Q4 FY2026 · quarter ended Dec 2025
Purchases of investments of -$16.43M in Q4 FY2026
Q4 FY2026 purchases of investments was -$16.43M. Trailing-twelve-month purchases of investments was -$15.42M.
Context
- Purchases of investments amounted to 115.2% of revenue in FY2026.
- Purchases of investments grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly purchases of investments holds near -$16.43M or moves back toward the trailing-twelve-month quarterly average of -$3.85M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2026
- (84.78M) USD
- Year-over-year change
- -177.3%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2026 | 2025-12-31 | (84.78M) | -177.3% |
| FY2025 | 2025-04-30 | (30.57M) | +83.8% |
| FY2024 | 2024-04-30 | (189.23M) | -92.6% |
| FY2023 | 2023-04-30 | (98.25M) | +28.2% |
| FY2022 | 2022-04-30 | (136.92M) | — |
Purchases of Investments vs competitors
How KALV compares with its peers on the latest reported figures
- KALV's LTM Dec 2025 purchases of investments of $15.42M is the 7th largest of the 10 companies compared; the peer median is $151.09M.
- Purchases of investments amounts to 13.3% of revenue for KALV, versus a peer median of 42.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $427.81M | -7.3% | +32.8% | — | |
| LTM Mar 2026 | $342.26M | +5.5% | +42.4% | 387.9% | |
| LTM Mar 2026 | $185.91M | -62.9% | -24.4% | 1879.2% | |
| LTM Mar 2026 | $155.76M | +217.1% | +74.5% | 52.0% | |
| LTM Mar 2026 | $151.09M | -70.4% | -1.6% | 272.1% | |
| LTM Mar 2026 | $16.02M | — | — | 32.3% | |
| LTM Dec 2025 | $15.42M | — | — | 13.3% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding KALV) | $151.09M | -7.3% | +32.8% | 42.1% | |
Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (82.34M) | (92.91M) | (126.64M) | (183.44M) | (164.29M) |
| Depreciation & Amortization | 743K | 718K | 816K | 941K | 1.45M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 9.92M | 21.92M | 12.29M | 0 |
| Change in Working Capital | (12.32M) | 7.41M | 15.17M | 15.04M | 954K |
| Accounts Receivables | (5.2M) | (2.32M) | 8.18M | (3.62M) | (7.4M) |
| Inventory | 0 | 0 | 0 | 0 | (3.43M) |
| Accounts Payables | 1.69M | 1.11M | 4.32M | (4.97M) | 4.19M |
| Other Working Capital | (8.81M) | 8.62M | 2.67M | 23.63M | 7.59M |
| Other Non-Cash Items | 15.78M | (407K) | (485K) | 2.27M | 80.26M |
| Operating Cash Flow | (78.13M) | (75.26M) | (89.23M) | (152.91M) | (81.62M) |
| Capital Expenditures | (931K) | (1.2M) | (443K) | (434K) | (1.71M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (136.92M) | (98.25M) | (189.23M) | (30.57M) | (84.78M) |
| Sales of Investments | 195.71M | 140.86M | 104.96M | 122.52M | 105.36M |
| Other Investing Activities | 0 | 0 | (401K) | 0 | 0 |
| Investing Cash Flow | 57.86M | 41.42M | (84.72M) | 91.02M | 18.68M |
| Debt Repayment | 0 | 0 | 0 | 98.04M | 160.72M |
| Common Stock Issued | 1.58M | 56.58M | 96.95M | 61.69M | 1.92M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.53M | 53.77M | 0 | 0 |
| Financing Cash Flow | 1.58M | 58.12M | 150.71M | 159.73M | 162.64M |
| Effect of Forex Changes | (1.17M) | 1.24M | (1.21M) | 1.98M | (1.98M) |
| Net Change in Cash | (19.86M) | 25.51M | (24.45M) | 99.83M | 97.73M |
| Free Cash Flow | (79.07M) | (76.46M) | (89.67M) | (153.34M) | (83.33M) |
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
Intrinsic Alpha fair value
Locked
Current Price
$27.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.